I posted this yesterday
….the market is totally focused on existing revenue streams (drugs on market) and if they may be slightly downgraded in the near term (which has an immaterial impact on future earnings) and are missing the far bigger pipeline opportunities (5-10x) that in each case open up markets that are multiples of their existing revenue streams. (Melissa Benson, Wilsons Advisory)
Today, Neuren announced the third successive successful Phase 2 result for NNZ-2591. However, in line with those comments yesterday, the market appeared to remain anally fixated on a slight downgrade in projected royalty revenue from DayBue.
To keep it simple, there were two headlines of key significance in the Angelman results presentation today
Results further strengthen confidence in potential of NNZ-2591 for multiple neurodevelopmental disorders, independent of origin of underlying genetics
Phase 2 trial results validating multi-indication platform
This is the main game and this should be the focus – today’s third successful result surely validates NNZ-2591 as a multi-indication platform, aka a “pipeline-in-a-drug”.
- Forums
- ASX - By Stock
- NEU
- Ann: Phase 2 trial shows significant improvements in Angelman
Ann: Phase 2 trial shows significant improvements in Angelman, page-72
-
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$12.86 |
Change
-0.150(1.15%) |
Mkt cap ! $1.644B |
Open | High | Low | Value | Volume |
$12.80 | $12.89 | $12.69 | $2.328M | 182.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1 | $12.86 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.87 | 570 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 481 | 12.810 |
10 | 980 | 12.800 |
4 | 623 | 12.790 |
4 | 1064 | 12.780 |
4 | 771 | 12.770 |
Price($) | Vol. | No. |
---|---|---|
12.820 | 61 | 2 |
12.830 | 685 | 6 |
12.840 | 756 | 6 |
12.850 | 972 | 5 |
12.860 | 673 | 6 |
Last trade - 12.44pm 16/10/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
SPONSORED BY The Market Online